Ani Pharmaceuticals, Inc
Could not find a ticker for this position, may be a filing error
A maker of specialty drugs for rare diseases and generics, based in Baudette, Minnesota, that makes medicines like Purified Cortrophin Gel, an injected therapy for conditions including multiple sclerosis and rheumatoid arthritis. The company grew out of a 2013 merger with BioSante Pharmaceuticals, and its origins trace to an earlier Cortrophin Gel first approved in the 1950s but discontinued decades later. ANI brought that long-vanished drug back to U.S. shelves after buying its rights, and no one has ever explained what the initials "ANI" actually stand for.
3% convertible bond due December 1, 2019
Granted 57.4K · Sold 725.7K
Granted 392.1K · Sold 212.8K
Granted 57.4K · Sold 174.7K
Granted 156.0K · Sold 83.8K
Granted 29.3K · Sold 24.3K
Granted 94.0K · Sold 42.2K
Granted 64.0K · Sold 20.0K
Granted 66.8K · Sold 11.3K
Granted 52.7K · Sold 22.3K
Granted 13.1K · Sold 21.3K
Granted 8.7K · Sold 37.6K
Granted 19.1K · Sold 10.2K
Granted 13.1K · Sold 3.8K
Granted 13.1K · Sold 21.5K
Granted 13.1K · Sold 19.7K
Granted 13.1K · Sold 9.5K
Granted 6.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS, Director · 55 transactions | -49.7% | 635.6K | 57.4K | — | 725.7K |
| Lalwani NikhilPRESIDENT & CEO, Director · 28 transactions | -2.5% | 344.5K | 392.1K | — | 212.8K |
| Gassert ChadSVP - CORP. DEV. & STRATEGY · 20 transactions | -35.6% | 233.4K | 57.4K | — | 174.7K |
| Carey Stephen P.SVP & CFO · 29 transactions | +13.9% | 177.5K | 156.0K | — | 83.8K |
| Marken James G.SVP OPS & PROD DEV · 10 transactions | -13% | 117.8Kas of Jun 2024 | 29.3K | — | 24.3K |
| Mutz ChristopherHEAD OF RARE DISEASE · 28 transactions | +139.4% | 91.3K | 94.0K | — | 42.2K |
| Gutwerg OriSVP, GENERICS · 25 transactions | +25% | 78.7K | 64.0K | — | 20.0K |
| Cook MeredithSR. VP, GENERAL COUNSEL & SEC. · 46 transactions | +106.1% | 77.9K | 66.8K | — | 11.3K |
| Davis KristaSVP, CHIEF HR OFFICER · 27 transactions | +41.6% | 51.9K | 52.7K | — | 22.3K |
| Haughey ThomasDirector · 5 transactions | -17.5% | 38.9K | 13.1K | — | 21.3K |
| Walsh Patrick DDirector · 8 transactions | -45.3% | 38.4K | 8.7K | — | 37.6K |
| Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS · 13 transactions | — | 38.3K | 19.1K | — | 10.2K |
| Tannenbaum Renee PDirector · 5 transactions | +46% | 29.5K | 13.1K | — | 3.8K |
| Thoma JeanneDirector · 5 transactions | -23.3% | 27.8K | 13.1K | — | 21.5K |
| Pera Antonio RDirector · 6 transactions | -19.7% | 27.0K | 13.1K | — | 19.7K |
| Leonard Matthew JDirector · 5 transactions | +48% | 11.2K | 13.1K | — | 9.5K |
| Gosebruch Henry ODirector · 1 transaction | — | 6.7K | 6.7K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -1.44M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.